Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangxin Dingji Granules (养心定悸颗粒) is a traditional Chinese medicine (TCM) formulation developed and manufactured by Guhan Chinese Medicine, a subsidiary of Guhan Pharmaceutical Group. Derived from the classic TCM formula Zhigancao Decoction (炙甘草汤) from the Treatise on Febrile Diseases (Shanghan Lun), it is composed of nine active herbal ingredients: Rehmanniae Radix, Ophiopogonis Radix, Ginseng Rubra Radix et Rhizoma, Jujubae Fructus, Asini Corii Colla, Sesami Semen Nigrum, Cinnamomi Ramulus, Zingiberis Rhizoma Recens, and Glycyrrhizae Radix et Rhizoma Praeparata cum Melle. The formulation is indicated for nourishing blood, replenishing qi, restoring pulse, and relieving palpitations. It is clinically used to treat symptoms such as palpitations, shortness of breath, arrhythmia, night sweats, insomnia, dry throat, and constipation caused by qi and blood deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yangxin Dingji Granules.